Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Amyloidosis.

Morie A Gertz1, Martha Q Lacy, Angela Dispenzieri

  • 1Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. gertz.morie@mayo.edu

Best Practice & Research. Clinical Haematology
|July 20, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis.

Circulation·2018
Same author

Publisher Correction: The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group.

Nature reviews. Nephrology·2018
Same author

Staging systems use for risk stratification of systemic amyloidosis in the era of high-sensitivity troponin T assay.

Blood·2018
Same author

Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome.

Blood cancer journal·2018
Same author

Autologous Stem Cell Transplant for IgM-Associated Amyloid Light-Chain Amyloidosis.

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation·2018
Same author

Peripheral blood biomarkers of early immune reconstitution in newly diagnosed multiple myeloma.

American journal of hematology·2018
Same journal

CAR-T cell therapy for multiple myeloma: An update on the current state and future potential.

Best practice & research. Clinical haematology·2025
Same journal

Cancer vaccines in hematologic malignancy: A systematic review of the rational and evidence for clinical use.

Best practice & research. Clinical haematology·2025
Same journal

Immune therapy of haematological cancers.

Best practice & research. Clinical haematology·2025
Same journal

Advances in NK cell therapy for multiple myeloma.

Best practice & research. Clinical haematology·2025
Same journal

Adoptive cellular therapies in multiple myeloma.

Best practice & research. Clinical haematology·2025
Same journal

Bispecific T-cell engager therapy for multiple myeloma.

Best practice & research. Clinical haematology·2025
See all related articles

Amyloidosis, a rare plasma-cell disorder, presents with diverse symptoms, making diagnosis challenging. This review outlines a diagnostic pathway, prognosis assessment, and therapeutic strategies for this uncommon condition.

Area of Science:

  • Hematology
  • Oncology
  • Nephrology

Background:

  • Amyloidosis is an uncommon plasma-cell dyscrasia with a low incidence rate.
  • Diagnosis is often delayed due to nonspecific and varied symptoms like fatigue, dyspnea, and edema.
  • Clinical presentations include nephrotic syndrome, cardiomyopathy, neuropathy, and autonomic failure.

Purpose of the Study:

  • To provide a diagnostic pathway for clinicians to identify amyloidosis.
  • To review methods for assessing patient prognosis.
  • To outline logical therapeutic strategies for managing amyloidosis.

Main Methods:

  • Utilizing the free light chain assay for improved patient evaluation.
  • Employing cardiac biomarkers for prognostic assessment.

Related Experiment Videos

  • Reviewing recent advancements in diagnostic and therapeutic approaches.

    • Main Results:

    • Recent advances include the free light chain assay and cardiac biomarkers for evaluation and prognosis.
    • Therapeutic strategies have evolved, incorporating high-dose and intermediate-dose chemotherapy.
    • A structured diagnostic and therapeutic pathway is presented.

    Conclusions:

    • Early and accurate diagnosis of amyloidosis is crucial for effective management.
    • Integrating new diagnostic tools and prognostic markers improves patient outcomes.
    • This review offers a framework for diagnosing, assessing prognosis, and planning treatment for amyloidosis.